. 2020 Mar 17;12(3):275. doi: 10.3390/pharmaceutics12030275

Table 2.

Properties of DFOA, MTP, PYR, and RIF and results of polymer drug release studies. The fold change in affinity due to inclusion complex was calculated from PyRx results (lower value indicates greater affinity binding). Maximum total drug released, and days of continuous, above assay background release are listed above the corresponding polymer type per each drug.

Drug	Mol. Wt.(g/mol)	Solubility (PBS, 25 °C, mg/mL)	β-CD/Dex Affinity Ratio	Max Total Release (mg)	Days of Release
Deferoxamine	560.68	5.0	0.193	1.7 ± 0.92	30
Deferoxamine	560.68	5.0	0.193	pCD-β-MP	Disks
Metyrapone	226.27	0.43	0.012	5.0 ± 0.53	30
Metyrapone	226.27	0.43	0.012	pCD-β-disk	All polymers
Pyrvinium	382.52	0.00029	0.022	1.6 ± 0.30	30
Pyrvinium	382.52	0.00029	0.022	pCD-β-MP	All polymers
Rifampicin	822.94	2.5	0.023	1.9 ± 0.21	30
Rifampicin	822.94	2.5	0.023	Dex-disk	Disks